Auvelity (Dextromethorphan HBr and Bupropion HCl) Auvelity is a new prescriptive agent that is the first of its kind. This medication is used in the treatment of Major Depressive Disorder (MDD) in a unique way. This oral medication acts on the N-methyl D-aspartate (NMDA) receptors in the brain, unlike most other treatment options for depression. This medication became FDA approved for the treatment of MDD in adults in August 2022 and is the first oral NMDA receptor antagonist
